323990.KQ KOE
Vaxcell-Bio Therapeutics Co., Ltd.
1W: +1.8%
1M: -15.5%
3M: -12.2%
YTD: -58.0%
1Y: -54.3%
3Y: -86.2%
5Y: -94.3%
₩4,285.00 ($3.17)
-25.00 (-0.58%)
Weekly Expected Move ±7.6%
₩3630
₩3958
₩4285
₩4612
₩4940
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Income Trends
Revenue
$7.1B
+271.6% ▲
Gross Profit
-$1.1B
-395.0% ▼
Operating Income
-$15.6B
-3.7% ▼
Net Income
-$13.3B
-25.6% ▼
EPS (Diluted)
$-524.51
-13.3% ▼
EBITDA
-$13.4B
-50.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $14M | $1.9B | $7.1B |
| YoY Growth | +0.0% | +0.0% | +0.0% | +13737.3% | +271.6% |
| Cost of Revenue | $19M | $16M | $7M | $1.5B | $8.1B |
| Gross Profit | -$19M | -$16M | $7M | $365M | -$1.1B |
| Gross Margin | — | — | 51.9% | 19.2% | -15.2% |
| R&D Expenses | $1.8B | $2.1B | $4.9B | $6.0B | $0 |
| SG&A Expenses | $1.6B | $2.3B | $3.2B | $3.5B | $3.2B |
| Operating Expenses | $5.9B | $8.2B | $11.5B | $15.4B | $14.5B |
| Operating Income | -$5.9B | -$8.2B | -$11.5B | -$15.0B | -$15.6B |
| Operating Margin | — | — | -83851.3% | -791.9% | -221.0% |
| Interest Expense | $27M | $17M | $44M | $225M | $225M |
| Income Before Tax | -$4.8B | -$6.8B | -$10.3B | -$10.6B | -$13.3B |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$4.8B | -$6.8B | -$10.3B | -$10.6B | -$13.3B |
| Net Margin | — | — | -74865.8% | -559.4% | -189.1% |
| EPS (Diluted) | $-315.00 | $-337.56 | $-524.00 | $-463.00 | $-524.51 |
| EBITDA | -$4.5B | -$6.5B | -$9.8B | -$8.9B | -$13.4B |
| Shares Outstanding | 15M | 20M | 20M | 23M | 23M |